Variety Of Novel Approaches Marks Next-Gen Cancer Therapies At AACR
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The annual meeting of the American Association for Cancer Research has always been a venue for biotechs to display innovative approaches to treating cancer – perhaps catching the eye of an investor – and the 2011 meeting didn't disappoint.
You may also be interested in...
Incyte Further Enhances IO Pipeline With Calithera's Arginase Inhibitor
In its second cancer deal in two months, Incyte licenses a first-in-class asset expected to offer potential cancer immunotherapy synergy with IDO1 and checkpoint inhibition.
Can Wealth Of Molecular Data Enable Promise Of Chemoprevention?
The same advances in scientific understanding of the molecular basis of cancer that have propelled the rise of targeted oncologics also hold out the tantalizing prospect of expanded chemoprevention in cancer, the American Association for Cancer Research suggests in its Cancer Progress Report 2011.
Can Wealth Of Molecular Data Enable Promise Of Chemoprevention?
The same advances in scientific understanding of the molecular basis of cancer that have propelled the rise of targeted oncologics also hold out the tantalizing prospect of expanded chemoprevention in cancer, the American Association for Cancer Research suggests in its Cancer Progress Report 2011.